Tregalizumab
N
Y (what is this?) (verify) Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, et al. (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunology and Cell Biology. 93 (4): 396–405. doi:10.1038/icb.2014.102. PMC 4407014. PMID 25512343.
- ^ König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology. 7: 11. doi:10.3389/fimmu.2016.00011. PMC 4724712. PMID 26834751.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
